Advanced search
Publication Cover
Scandinavian Journal of Urology and Nephrology Volume 42, 2008 - Issue 3
Submit an article Journal homepage
352
Views
47
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

Dr Per Olov Hedlund Department of Urology, Karolinska University Hospital Solna, SwedenCorrespondence[email protected]
,
Jan-Erik Damber Department of Urology, Sahlgrens University Hospital, Gothenburg, Sweden
,
Inger Hagerman Department of Cardiology, Karolinska University Hospital, Huddinge, Sweden
,
Svein Haukaas Diakonissehjemmet Hospital, Bergen, Norway
,
Peter Henriksson Department of Medicine, Danderyd University Hospital, Danderyd, Sweden
,
Peter Iversen Department of Urology, Rigshospitalet, Copenhagen, Denmark
,
Robert Johansson Oncologic Center, Umeå University Hospital, Umeå, Sweden
,
Peter Klarskov Department of Urology, Herlev University Hospital, Herlev, Denmark
,
Finn Lundbeck Department of Urology, Skejby University Hospital, Aarhus, Denmark
,
Finn Rasmussen Department of Urology, Herlev University Hospital, Herlev, Denmark
,
Eberhard Varenhorst Department of Urology, Linköping University Hospital, Linköping, Sweden
,
Jouko Viitanen Department of Urology, North Karjala Central Hospital, Joensuu, Finland
, The Spcg-5 Study Group,
Dr Per Olov Hedlund Department of Urology, Karolinska University Hospital Solna, SwedenCorrespondence[email protected]
,
Jan-Erik Damber Department of Urology, Sahlgrens University Hospital, Gothenburg, Sweden
,
Inger Hagerman Department of Cardiology, Karolinska University Hospital, Huddinge, Sweden
,
Svein Haukaas Diakonissehjemmet Hospital, Bergen, Norway
,
Peter Henriksson Department of Medicine, Danderyd University Hospital, Danderyd, Sweden
,
Peter Iversen Department of Urology, Rigshospitalet, Copenhagen, Denmark
,
Robert Johansson Oncologic Center, Umeå University Hospital, Umeå, Sweden
,
Peter Klarskov Department of Urology, Herlev University Hospital, Herlev, Denmark
,
Finn Lundbeck Department of Urology, Skejby University Hospital, Aarhus, Denmark
,
Finn Rasmussen Department of Urology, Herlev University Hospital, Herlev, Denmark
,
Eberhard Varenhorst Department of Urology, Linköping University Hospital, Linköping, Sweden
,
Jouko Viitanen Department of Urology, North Karjala Central Hospital, Joensuu, Finland
& The Spcg-5 Study Group show all
Pages 220-229 | Received 01 Oct 2007, Published online: 09 Jul 2009

Citations (47)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (10)

Midas B. Mulder, Erwin Birnie, Caroline van Dijck – van Boetzelaer, Gert-Jan van de Geijn, Egbert Boevé, Elsbeth M. Westerman & Paul Hamberg. (2021) Unsafe testosterone-based dosing regimen of androgen deprivation therapy in patients with locally advanced or metastatic prostate cancer: a prematurely ended randomized controlled trial (MIDAS-trial). Acta Oncologica 60:4, pages 539-543.
Read now
Mads Hvid Poulsen, Jørn Skibsted Jakobsen, Mike Allan Mortensen, Poul Flemming Høilund-Carlsen & Lars Lund. (2019) Does therapy of the primary tumor matter in oligometastatic prostate cancer? A prospective 10-year follow-up study. Research and Reports in Urology 11, pages 215-221.
Read now
Antti Kaipia & Harri Visapää. (2017) The complex interplay of sex steroids manifested by endocrine treatment of prostate cancer. Scandinavian Journal of Urology 51:3, pages 206-211.
Read now
Rami Klaff, Eberhard Varenhorst, Anders Berglund, Per Olov Hedlund, Folke Sjöberg & Gabriel Sandblom. (2016) Clinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patients. Scandinavian Journal of Urology 50:5, pages 352-359.
Read now
Syed I. A. Shah, Paul D. Abel, Trinh Duong, Pat Price & Ruth Langley. (2014) Parenteral oestrogen: Effective and safer than both oral oestrogen and contemporary androgen deprivation therapy for prostate cancer?. Scandinavian Journal of Urology 48:4, pages 411-412.
Read now
Rafal Turo, Michal Smolski, Rachel Esler, Magda L. Kujawa, Stephen J. Bromage, Neil Oakley, Adebanji Adeyoju, Stephen C. W. Brown, Richard Brough, Andrew Sinclair & Gerald N. Collins. (2014) Diethylstilboestrol for the treatment of prostate cancer: past, present and future. Scandinavian Journal of Urology 48:1, pages 4-14.
Read now
Louise L. Klarskov, Peter Klarskov, Søren Mommsen & Niels Svolgaard. (2012) Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: A long-term prospective study. Scandinavian Journal of Urology and Nephrology 46:1, pages 37-43.
Read now
Per Olov Hedlund, Robert Johansson, Jan Erik Damber, Inger Hagerman, Peter Henriksson, Peter Iversen, Peter Klarskov, Peter Mogensen, Finn Rasmussen & Eberhard Varenhorst. (2011) Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: Evaluation of cardiovascular events in a randomized trial. Scandinavian Journal of Urology and Nephrology 45:5, pages 346-353.
Read now
Shandra Wilson. (2009) Update on the management of prostate cancer with goserelin acetate: patient perspectives. Cancer Management and Research 1, pages 99-105.
Read now
Arto Mikkola, Jussi Aro, Sakari Rannikko, Mirja Ruutu & The Finnprostate Group. (2009) Prognostic grouping of metastatic prostate cancer using conventional pretreatment prognostic factors. Scandinavian Journal of Urology and Nephrology 43:4, pages 265-270.
Read now

Articles from other publishers (37)

Richard J. Wassersug, Paul F. Schellhammer & Erik Wibowo. (2024) Re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3–7. European Urology.
Crossref
Johannes Huber, Michael Fröhner, Manfred Wirth, Jörg Kotzerke, Claudia Brogsitter & Tobias Hölscher. 2023. Die Urologie. Die Urologie 1593 1616 .
Herjan J T Coelingh Bennink, Jan Krijgh, Jan F M Egberts, Maria Slootweg, Harm H E van Melick, Erik P M Roos, Diederik M Somford, Yvette Zimmerman, Iman J Schultz, Noel W Clarke, R Jeroen A van Moorselaar & Frans M J Debruyne. (2022) Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review. Endocrine Connections 11:12.
Crossref
Johannes Huber, Michael Fröhner, Manfred Wirth, Jörg Kotzerke, Claudia Brogsitter & Tobias Hölscher. 2020. Die Urologie. Die Urologie 1 24 .
Ryan W. Dobbs, Neha R. Malhotra, David T. Greenwald, Alice Y. Wang, Gail S. Prins & Michael R. Abern. (2018) Estrogens and prostate cancer. Prostate Cancer and Prostatic Diseases 22:2, pages 185-194.
Crossref
Mark J. Salji, Imran Ahmad, Sarah Slater, Fat‐Wui Poon, Abdulla Alhasso, Nadja V. Melquiot, Holly Bekarma, Jane Hendry & Hing Y. Leung. 2019. Blandy's Urology. Blandy's Urology 563 609 .
Liang Dong, Richard C. Zieren, Wei Xue, Theo M. de Reijke & Kenneth J. Pienta. (2019) Metastatic prostate cancer remains incurable, why?. Asian Journal of Urology 6:1, pages 26-41.
Crossref
Darren Ming‐Chun Poon, Chi‐Kwok Chan, Tim‐Wai Chan, Foon‐Yiu Cheung, Philip Wai‐Kay Kwong, Eric Ka‐Chai Lee, Angus Kwong‐Chuen Leung, Simon Yiu‐Lam Leung, Wai‐Kit Ma, Hing‐Shing So, Po‐Chor Tam & Lap‐Yin Ho. (2018) Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro‐Oncology. BJU International 121:5, pages 703-715.
Crossref
Antonello Veccia, Francesca Maines & Orazio Caffo. (2017) Cardiovascular toxicities of systemic treatments of prostate cancer: is oestrogen to the rescue?. Nature Reviews Urology 14:9, pages 575-575.
Crossref
Syed Imran A. Shah, Hannah C. P. Wilson & Paul D. Abel. (2017) Cardiovascular toxicities of systemic treatments of prostate cancer: oestrogen to the rescue?. Nature Reviews Urology 14:9, pages 575-575.
Crossref
Nicholas Russell, Ada Cheung & Mathis Grossmann. (2017) Estradiol for the mitigation of adverse effects of androgen deprivation therapy. Endocrine-Related Cancer 24:8, pages R297-R313.
Crossref
Mohamed Hosny Osman, Eman Farrag, Mai Selim, Mohamed Samy Osman, Arwa Hasanine & Azza Selim. (2017) Cardiac glycosides use and the risk and mortality of cancer; systematic review and meta-analysis of observational studies. PLOS ONE 12:6, pages e0178611.
Crossref
Tobias Gramann & Hans-Peter Schmid. 2017. Management of Prostate Cancer. Management of Prostate Cancer 313 325 .
Rami Klaff, Anders Berglund, Eberhard Varenhorst, Per Olov Hedlund, Morten Jǿnler & Gabriel Sandblom. (2015) Clinical characteristics and quality‐of‐life in patients surviving a decade of prostate cancer with bone metastases. BJU International 117:6, pages 904-913.
Crossref
Ruth E. Langley, Howard G. Kynaston, Abdulla A. Alhasso, Trinh Duong, Edgar M. Paez, Gordana Jovic, Christopher D. Scrase, Andrew Robertson, Fay Cafferty, Andrew Welland, Robin Carpenter, Lesley Honeyfield, Richard L. Abel, Michael Stone, Mahesh K.B. Parmar & Paul D. Abel. (2016) A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol. European Urology 69:6, pages 1016-1025.
Crossref
Eberhard Varenhorst, Rami Klaff, Anders Berglund, Per Olov Hedlund & Gabriel Sandblom. (2016) Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases. Cancer Medicine 5:3, pages 407-414.
Crossref
S. I. A. Shah, H. C. P. Wilson & P. D. Abel. (2016) First, do no harm, second, do some good, third, give choice and fourth, save cash: the 1, 2, 3 and 4 of transdermal oestradiol as androgen deprivation therapy ticks all the boxes. Internal Medicine Journal 46:2, pages 241-243.
Crossref
Johannes Huber, Claudia Brogsitter, Jörg Kotzerke, Tobias Hoelscher, Michael Baumann, Michael Fröhner & Manfred Wirth. 2016. Die Urologie. Die Urologie 1363 1383 .
B. Šošić-Jurjević, B. Filipović, K. Renko, M. Miler, S. Trifunović, V. Ajdžanovič, J. Kӧhrle & V. Milošević. (2015) Testosterone and estradiol treatments differently affect pituitary-thyroid axis and liver deiodinase 1 activity in orchidectomized middle-aged rats. Experimental Gerontology 72, pages 85-98.
Crossref
Arie Carneiro, Andre Deeke Sasse, Andrew Aurel Wagner, Guilherme Peixoto, André Kataguiri, Ary Serpa Neto, Bianca Alves Vieira Bianco, Peter Chang, Antônio Carlos Lima Pompeo & Marcos Tobias-Machado. (2014) Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World Journal of Urology 33:9, pages 1281-1289.
Crossref
Syed Imran Ali Shah. (2020) Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer. South Asian Journal of Cancer 04:02, pages 095-097.
Crossref
Hocine Habchi & Nicolas Mottet. (2015) Androgen Deprivation Therapy in Prostate Cancer - Current Status in M1 Patients. Oncology Research and Treatment 38:12, pages 646-652.
Crossref
Johannes Huber, Claudia Brogsitter, Jörg Kotzerke, Tobias Hölscher, Michael Baumann, Michael Fröhner & Manfred Wirth. 2015. Die Urologie. Die Urologie 1 29 .
Loubina Fazal, Feriel Azibani, Nicolas Vodovar, Alain Cohen Solal, Claude Delcayre & Jane‐Lise Samuel. (2014) Effects of biological sex on the pathophysiology of the heart. British Journal of Pharmacology 171:3, pages 555-566.
Crossref
Syed I.A. Shah, Fay H. Cafferty, Ruth E. Langley & Paul D. Abel. (2014) Re: Androgen Deprivation Therapy: Impact on Quality of Life and Cardiovascular Health. The Journal of Sexual Medicine 11:1, pages 314-315.
Crossref
Syed Imran Ali Shah, Ruth E. Langley, Fay H. Cafferty, Richard L. Abel & Paul D. Abel. (2013) Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU International 112:7.
Crossref
Erik Wibowo & Richard J. Wassersug. (2013) The effect of estrogen on the sexual interest of castrated males: Implications to prostate cancer patients on androgen-deprivation therapy. Critical Reviews in Oncology/Hematology 87:3, pages 224-238.
Crossref
S I A Shah, P D Abel, R E Langley & F H Cafferty. (2013) Comment on ‘Endocrine therapy in prostate cancer: time for re-appraisal of risks, benefits and cost-effectiveness?’. British Journal of Cancer 108:10, pages 2192-2193.
Crossref
Ruth E Langley, Fay H Cafferty, Abdulla A Alhasso, Stuart D Rosen, Subramanian Kanaga Sundaram, Suzanne C Freeman, Philip Pollock, Rachel C Jinks, Ian F Godsland, Roger Kockelbergh, Noel W Clarke, Howard G Kynaston, Mahesh KB Parmar & Paul D Abel. (2013) Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). The Lancet Oncology 14:4, pages 306-316.
Crossref
Fay H. Cafferty, Ruth E. Langley & Paul D. Abel. (2013) Use of transdermal estrogen in the management of advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations 31:2, pages 279.
Crossref
Erik Wibowo & Richard J. Wassersug. (2013) Does the timing of estrogen administration after castration affect its ability to preserve sexual interest in male rats? — Exploring the critical period hypothesis. Physiology & Behavior 110-111, pages 63-72.
Crossref
Suresh Venugopal & John Anderson. 2012. Management of Prostate Cancer. Management of Prostate Cancer 239 250 .
Charlotte E. Almasi, Klaus Brasso, Peter Iversen, Helle Pappot, Gunilla Høyer‐Hansen, Keld Danø & Ib J. Christensen. (2010) Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. The Prostate 71:8, pages 899-907.
Crossref
Ruth E. Langley, Patricia Price & Paul D. Abel. (2011) Re: Claude C. Schulman, Jacques Irani, Juan Morote, et al. Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. Eur Urol Suppl 2010;9:675–91. European Urology 59:4, pages e24-e25.
Crossref
Ruth Langley, Pat Price, Philip Pollock & Paul D. Abel. (2010) Osteoporosis in patients with prostate cancer on long‐term androgen deprivation therapy: an increasing but under‐recognised problem. BJU International 106:5, pages 726-727.
Crossref
Alvan J. Pope & Paul D. Abel. (2010) Androgen deprivation therapy for prostate cancer and its complications. Trends in Urology, Gynaecology & Sexual Health 15:3, pages 32-37.
Crossref
. (2009) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 16:3, pages 260-277.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.